tradingkey.logo

cbdMD Inc

YCBD
查看詳細走勢圖
1.490USD
-0.440-22.80%
收盤 12/19, 16:00美東報價延遲15分鐘
13.27M總市值
虧損本益比TTM

cbdMD Inc

1.490
-0.440-22.80%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-22.80%

5天

+24.17%

1月

+195.81%

6月

+81.71%

今年開始到現在

-50.33%

1年

-48.26%

查看詳細走勢圖

TradingKey cbdMD Inc股票評分

單位: USD 更新時間: 2025-12-19

操作建議

cbdMD Inc當前公司基本面數據相對健康,增長潛力很大。當前估值合理,在藥品行業排名109/158位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價2.00。中期看,股價處於上升通道。近一個月,市場表現很強,基本面評分較高,但很強的走勢沒有得到技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

cbdMD Inc評分

相關信息

行業排名
109 / 158
全市場排名
308 / 4582
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 1 分析師
買入
評級
2.000
目標均價
+213.19%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

cbdMD Inc亮點

亮點風險
cbdMD, Inc. is a cannabidiol (CBD) company. The Company has a comprehensive line of United States produced, THC-free CBD products, including NSF Certified for Sport products, as well as its new Full Spectrum products. The Company's flagship brands include cbdMD and Paw CBD, as well as its functional mushroom brand ATRx Labs. Its cbdMD brand includes high-grade, premium CBD products including CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD sleep aids and CBD drink products including its Herbal Oasis Social Tonic and an array of Farm Act compliant Delta 9 products. Its Paw CBD brand of pet products includes veterinarian-formulated products including tinctures, chews, topicals products in varying strengths, and its ATRx brand of natural functional mushroom support. Its cbdMD, Paw CBD and ATRx products are distributed through its e-commerce websites, third party e-commerce sites, select distributors and marketing partners as well as a variety of brick-and-mortar retailers.
業績增長期
公司處於發展階段,最新年度總收入19.19M美元
估值低估
公司最新PE估值-1.39,處於3年歷史低位
機構加倉
最新機構持股502.25K股,環比增加27.27%
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉,最新持倉0.00股
活躍度增加
近期活躍度增加,過去20天平均換手率-0.27

cbdMD Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

cbdMD Inc簡介

cbdMD, Inc. is a cannabidiol (CBD) company. The Company has a comprehensive line of United States produced, THC-free CBD products, including NSF Certified for Sport products, as well as its new Full Spectrum products. The Company's flagship brands include cbdMD and Paw CBD, as well as its functional mushroom brand ATRx Labs. Its cbdMD brand includes high-grade, premium CBD products including CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD sleep aids and CBD drink products including its Herbal Oasis Social Tonic and an array of Farm Act compliant Delta 9 products. Its Paw CBD brand of pet products includes veterinarian-formulated products including tinctures, chews, topicals products in varying strengths, and its ATRx brand of natural functional mushroom support. Its cbdMD, Paw CBD and ATRx products are distributed through its e-commerce websites, third party e-commerce sites, select distributors and marketing partners as well as a variety of brick-and-mortar retailers.
公司代碼YCBD
公司cbdMD Inc
CEOKennedy (T. Ronan)
網址https://www.cbdmd.com/

常見問題

cbdMD Inc(YCBD)的當前股價是多少?

cbdMD Inc(YCBD)的當前股價是 1.490。

cbdMD Inc 的股票代碼是什麼?

cbdMD Inc的股票代碼是YCBD。

cbdMD Inc股票的52週最高點是多少?

cbdMD Inc股票的52週最高點是6.538。

cbdMD Inc股票的52週最低點是多少?

cbdMD Inc股票的52週最低點是0.470。

cbdMD Inc的市值是多少?

cbdMD Inc的市值是13.27M。

cbdMD Inc的淨利潤是多少?

cbdMD Inc的淨利潤為-7.70M。

現在cbdMD Inc(YCBD)的股票是買入、持有還是賣出?

根據分析師評級,cbdMD Inc(YCBD)的總體評級為買入,目標價格為2.000。

cbdMD Inc(YCBD)股票的每股收益(EPS TTM)是多少

cbdMD Inc(YCBD)股票的每股收益(EPS TTM)是-1.138。
KeyAI